TG Therapeutics, Inc. (TGTX)
POSITIVEFondamental
63
Prix
$55.94
Capitalisation boursière
$8.21B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$800M
12 derniers mois (au 30/06/2026)
Résultat net
$441M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$-25M
Capitaux propres totaux
$648M
Passif total
$415M
Ratio de liquidité général
4.27
Couverture des intérêts
3.64
Dette/EBITDA
6.11
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$53.81
Prix actuel
$55.94
Marge de sécurité
-4.0%
Fourchette de juste valeur
$36.39 - $71.24
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
20.44
ROE
69.0%
Ratio P/B
14.19
P/FCF
493.15
Marge brute
82.4%
ROIC
7.8%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
7.8%
WACC
13.3%
ROIC − WACC
-5.5 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (16)
- EPS shows upward trend
- Price CAGR 27.86%
- ROIC 7.9%
- Gross Margin 82.4%
- Debt/Equity ratio
- Operating Margin 17.1%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 72.3%
- Revenue Growth 5Y 426.7%
- Analyst Consensus 86% Buy
- Net Margin Trend 55.2% vs 13.3%
Échoué (9)
- P/FCF 493.15
- P/B Ratio 14.19
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Surprise avg -53.8%
- Earnings Quality (OCF/NI) 0.04
- Share Dilution 3.6%
- Piotroski F-Score 4/9
Indisponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Michael S. Weiss Esq., J.D. | Chairman, CEO & President | 59 |
| Mr. Sean A. Power CPA | CFO, Corporate Secretary & Treasurer | 43 |
| Ms. Jenna Bosco | Senior Vice President of Corporate Communications | - |
| Mr. Adam Waldman | Chief Commercialization Officer | - |
Risque d'audit
9
Risque du conseil
10
Risque de rémunération
10
Risque droits des actionnaires
3
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for TGTX, sourced from Markets Gazette.
- 6/18/2026POSITIVETG Therapeutics Stock Rises Thursday: What's Driving The Gains?
TG Therapeutics Inc. experienced a notable stock increase on Thursday, fueled by positive investor sentiment surrounding recent clinical trial updates for its drug BRIUMVI. The ongoing positive reception to these developments suggests that the market is factoring in potential future revenue streams and market share gains for BRIUMVI. This sustained upward momentum indicates strong confidence in the company's drug development pipeline and its commercial prospects, potentially leading to further analyst upgrades and increased institutional interest.
- 2/26/2026NEUTRALTG Therapeutics (TGTX) Q4 2025 Earnings Transcript
TG Therapeutics (TGTX) has released the transcript of its Q4 2025 earnings conference call. While the document is now available, specific financial figures, future outlook, and management commentary have not been disclosed or are currently inaccessible. Investors are keenly awaiting a detailed analysis of this information to assess the company's performance during the period and its projections for the upcoming fiscal year. The lack of concrete data prevents an immediate evaluation of the stock's impact, keeping market sentiment on hold pending further clarification.
via Markets Gazette